Publication date: Sep 19, 2023
Breastmilk protects newborns from infections through specific and nonspecific compounds. This study investigated the neutralizing activity against SARS-CoV-2 of breastmilk from SARS-CoV-2 negative, unvaccinated mothers, and compared it to that from infected nursing mothers. We enrolled women after COVID-19 swab testing results upon maternity admission, and divided them into two groups: group A, COVID-19-positive mothers, and group B, negative mothers. Breastmilk was randomly sampled at 2, 7, and 20 days postpartum. We collected 19 samples for Group A and 41 for Group B. A microneutralization assay was used to determine the 50% neutralization (NT) titre. The presence of neutralizing antibodies was also determined. Group A had 100% neutralizing samples at 2 days postpartum (T0), declining 7 days postpartum (T1) and 20 days postpartum (T2). Group B samples exhibited neutralizing activity mostly at 7 days postpartum (T1) (90%). Negative mothers’ samples showed no correlation between NT titres and antibodies’ presence, suggesting that non-specific breastmilk components may exert antiviral action against SARS-CoV-2.
Open Access PDF
| Concepts | Keywords |
|---|---|
| 20days | Activity |
| Antibodies | Antibodies |
| Antiviral | Breastmilk |
| Breastmilk | Cov |
| Postpartum | Covid |
| Group | |
| Lactating | |
| Mothers | |
| Negative | |
| Neutralizing | |
| Postpartum | |
| Presence | |
| Sars | |
| Specific | |
| T1 |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | infections |
| disease | VO | unvaccinated |
| disease | IDO | assay |
| drug | DRUGBANK | Coenzyme M |
| disease | VO | vaccinated |
| disease | IDO | infection |
| disease | VO | vaccination |
| disease | VO | Viruses |
| disease | VO | pregnant women |
| disease | VO | population |
| disease | IDO | history |
| disease | VO | dose |
| disease | VO | vaccine |
| disease | MESH | asymptomatic infection |
| disease | IDO | facility |
| disease | VO | USA |
| disease | VO | titer |
| disease | VO | time |
| pathway | REACTOME | Fatty acids |
| disease | MESH | viral infections |
| disease | VO | Human immunodeficiency virus |